Inflammatory Profiles, Histopathological Features, and Remodeling Factors in Chronic Rhinosinusit… (NCT07528820) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Inflammatory Profiles, Histopathological Features, and Remodeling Factors in Chronic Rhinosinusitis With Nasal Polyps
Canada10 participantsStarted 2026-07-01
Plain-language summary
This study aims to examine three key aspects of chronic rhinosinusitis with nasal polyps (CRSwNP): inflammation, tissue structure (histopathology), and remodeling.
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Must be ≥19 of age at the time of signing the informed consent form
✓. Capable of giving signed informed consent.
✓. Having CRSwNP based on clinical symptoms and/or radiographic or endoscopic evidence of inflammation in their upper airways (Diagnosis consistent with EPOS 2020)2 and nasal polyp score (NPS) of at least 2 on each side
✓. Not expecting to have surgery within the next 7 months
Exclusion criteria
✕. A history of organ transplantation such as lung transplantation
✕. Previously or currently using immunomodulator or allergy medications or (including The allergy medications such as: a) First and second generations of Antihistamines (H1 blockers); b) Oral/Topical Decongestants; c) Oral or systemic corticosteroids; d) Leukotriene Receptor Antagonists; e) Mast Cell Stabilizers.
✕. A history of auto-immune diseases such as Rheumatoid arthritis and Systemic lupus erythematosus,
✕. Current or past sinonasal or bronchial tumors
✕. Currently using systemic or oral corticosteroids (such as Prednisone, Methylprednisolone)
✕. Current participation in any interventional treatment trials
✕. Diagnosed or suspected malignant or premalignant nasal disease (e.g. Schniderian Papilloma, unilateral nasal polyposis)
What they're measuring
1
Change in sinonasal inflammatory cytokine concentrations measured in nasal secretions using multiplex immunoassay
Timeframe: Baseline to 6 months
2
Change in sinonasal histopathological score assessed using semi-quantitative histopathological evaluation of nasal biopsy specimens